www 50jili fun

A pair of ruby red slippers worn by actress Judy Garland in the classic movie The Wizard of Oz is set to be auctioned off Saturday. The iconic sequinned pumps were once stolen from a Minnesota museum. But now they are expected to fetch as much as $3m (£2.35m) at auction, according to Heritage Auctions. Online bidding started a month ago, and as of noon local time on Saturday, the highest bid was $1.55m. Heritage Auctions has called these slippers the "Holy Grail of Hollywood memorabilia". Garland was only 16 when she played Dorothy in the classic 1939 musical The Wizard of Oz. Media outlet Variety ranked it second in its inaugural list of "100 Greatest Movies of All Time". The film is a musical adaptation of L. Frank Baum's 1900 children's book The Wonderful Wizard of Oz. While in the book, the magical slippers are silver, the producers for the film changed them to red to take advantage of the new Technicolor technology. In the film, as in the book, a pivotal moment occurs when Dorothy must click her heels three times as she repeats "There's no place like home" in order to leave the magical land of Oz and return to Kansas and her Auntie Em. While several pairs of shoes were worn by Garland during filming, only four are known to have survived. One of the pairs is on exhibit at the Smithsonian's National Museum of American History. But this pair up for auction has its own unique history. Collector Michael Shaw had loaned the slippers out to the Judy Garland Museum in her hometown of Grand Rapids, Minnesota, when they were stolen in 2005. Professional thief Terry Jon Martin used a hammer to smash the glass case and snatch the slippers, believing that their insured value of $1m must be because they were covered in actual gemstones. But when he took them to a "fence" - and intermediary who sells stolen goods to discreet buyers - he discovered they were just glass. So he gave the shoes to someone else. It wasn't until 2018 that the FBI recovered the shoes in a sting operation. What happened to them in those 13 years is still not known. In 2023, Martin - who was in his 70s and used a wheelchair - pleaded guilty to stealing them, and was sentenced to time served. "There's some closure, and we do know definitely that Terry Jon Martin did break into our museum, but I'd like to know what happened to them after he let them go," John Kelsch, curator of the Judy Garland Museum, told CBS News Minnesota in 2023 . "Just to do it because he thought they were real rubies and to turn them over to a jewelry fence. I mean, the value is not rubies. The value is an American treasure, a national treasure. To steal them without knowing that seems ludicrous."Wheel of Fortune contestants regularly whiff their bonus puzzles, but the winner of Monday, December 2’s episode was in for a particularly heartbreaking spin. Her additional letter choices added ZERO letters to a tricky puzzle, which was even more shocking since she had the advantage of a Wild Card wedge. The tough break involved Kelsey Sowders, a mom of three and steak/wine savant from Tomball, Texas. After an astounding performance, she proceeded to the coveted bonus round, having racked up $40,398 in cash, a prize trip to Japan, and the elusive Wild Card. This meant she got to pick five additional letters instead of four, which often spells success. Selecting “What are You Doing?” as her category, with the off-side support of her eldest son Grant and husband, Sowders joined Ryan Seacrest center stage. She landed on the star portion of the wheel, and the host assured, “Perhaps it’s good luck.” “I hope so,” Sowders said. The two-word puzzle read as “_EE_N_’ ‘_ _ S_,’ and she chose an additional “MFDA,” and H.” However, Vanna White didn’t move an inch as the letter choices were useless, making the puzzle very difficult. “Oh no!” Sowders exclaimed in disappointment. She went through the five stages of grief, staring in disbelief, blowing a raspberry in frustration, and recollecting herself. Seacrest wished her the best, “You’re doing great so far tonight.” But the cruel twist of fate left Sowder unable to solve the puzzle under the 10-second timer, which ended up being “KEEPING BUSY.” She was close, even able to get the first word, but nowhere near the second. “Oh no!” Sowders exclaimed once more as the full puzzle was displayed. Then, cutting back to the contestant and Seacrest, the second dagger came. The host revealed from his prize card contained $75,000 and she hid her face from it. “I don’t want to see that,” she said as Seacrest winced at the camera. “Don’t worry,” the host told her as she emotionally recovered and told him, “That’s okay.” The game show shared the big miss on YouTube, where fans expressed their shock and empathized with the player’s reaction. “That was a tough one. I didn’t get it either. Props to her for getting the first word right, but that second word was tricky as hell. I’m glad she’s not walking away empty-handed, though. She still won up until that point and nobody can take that from her,” one fan wrote. “Impossible without the right letter choices. Been a few of those this season,” wrote another. “If she would have won, she would have won over $100,000 cash without actually landing on the envelope! That’s really disappointing. Also, the fact that she had 5 letters but didn’t get a single one?! Should I be disappointed or impressed?” asked a third. 'Wheel of Fortune' Fans Demand Change After 'Crazy' Bonus Puzzle Pattern “Ouch!” wrote a fourth. “You don’t see $75,000 all that often!” Meanwhile , Seacrest had huge shoes to fill replacing the legendary Pat Sajak after four decades for Season 42. His debut month was the strongest ratings month for WoF in the past three years, and viewers were already treated to a viral moment (via a round of sausage) . That said, there have been some questionable host moments according to fans. In September, Seacrest suffered what fans dubbed his “first blooper” , involving a delayed reaction to rewarding a bonus round. Fans also called out the host for ruling against another player before the timer was up. Most controversially, fans recently called out the host for not reminding a player to pick a letter , leading to him losing the game in a misunderstanding and by a mere $147. Another puzzling pattern has emerged, which is that no player has won the bonus round in a full week , many fans blaming the players, not the host. As for Sowders, another contestant recently botched their bonus puzzle in a similar way after choosing poor letters, but in that instance, they didn’t have the boost of the Wild Card wedge. Wheel of Fortune , Weeknights, Check your local listings More Headlines: ‘Mistletoe Murders’: Sarah Drew Teases ‘Epic’ Finale Cliffhanger & Reveals Season 2 Hopes ‘Wheel of Fortune’ Contestant Devastated by Botched $75k Bonus Round Despite Big Boost How Did ‘Severance’ Season 1 End? ‘The Voice’ Season 26 Finale: Everything to Know ‘Wheel of Fortune’ Fans Go Wild Over Vanna White’s ‘Hot’ Son Nikko, 30, in Rare Video

Warren Hills boys, Phillipsburg girls bowling gain confidence with Greg Rottengen Tourney titlesNEW YORK — Contracts for Blake Snell and Tommy Edman increased the Los Angeles Dodgers' obligations for deferred payments to more than $1 billion owed to seven players from 2028-46. Snell's $182 million contract, announced Saturday, includes $66 million in deferred money payable to the pitcher through July 1, 2046, according to contract terms obtained by AP. Edman's $74 million, five-year deal, announced Friday, includes $25 million payable to the infielder and outfielder through July 1, 2044. Los Angeles now owes deferred payments of $1,006,500,000 to seven players from 2028-46. Snell's average is discounted to about $31.4 million annually for the Dodgers' luxury tax payroll and Edman to approximately $12.9 million. Snell gets a $52 million signing bonus payable on Jan. 25 and yearly salaries of $26 million, of which $13.2 annually will be deferred. The deferred money is payable in equal installments each July 1 from 2035-46. People are also reading... Los Angeles has a $10 million conditional club option for 2023 that could be exercised if Snell has a qualifying injury as specified in the contract and he spends 90 or more consecutive days on the injured list due to the qualifying injury and he has not been traded. If Snell is traded, he would receive a $5 million assignment bonus, payable by the acquiring team. He gets a hotel suite on road trips. Edman receives a $17 million signing bonus payable on Dec. 10, a $5 million salary next year and $12.25 million in each of the final four seasons, of which $6.25 million annually will be deferred. The Dodgers have a $13 million option for 2030 with a $3 million buyout. Two-way star Shohei Ohtani is due $680 million from 2034-43 as part of a record $700 million, 10-year contract through 2033. Infielder/outfielder Mookie Betts is owed $115 million in salaries from 2033-44 and the final $5 million of his signing bonus payable from 2033-35, all part of a $365 million, 12-year contract through 2032. First baseman Freddie Freeman is owed $57 million from 2028-40 in a $162 million, six-year contract through 2027. Catcher Will Smith is due $50 million payable from 2034-43 as part of a $140 million, 10-year contract through 2033. Outfielder Teoscar Hernández will get $8.5 million from 2030-39 as part of a $23.5 million, one-year deal for 2024. RED SOX: According to an AP source, left-handed reliever Aroldis Chapman agreed to a one-year deal worth $10.75 million with Boston. The deal is pending a physical. The move gives the Red Sox an option at closer with incumbent Kenley Jansen on the free agent market. The seven-time All-Star has a 2.63 ERA with 1,246 strikeouts in his 15-season career with seven teams. His 335 saves is 16th in baseball history. BRAVES: Right-hander Connor Gillispie will get an $820,000 salary while in the major leagues and $180,000 while in the minors as part of his one-year contract with Atlanta. The 27-year-old, who agreed to the deal on Friday, made his major league debut for Cleveland on Aug. 4 and had a 2.25 ERA in three relief appearances with the Guardians. ROYALS: Kansas City has reached an agreement with Diamond Sports Group to continue broadcasting Royals games next season, according to the team. Be the first to know Get local news delivered to your inbox!Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day

LOS ANGELES — Historically, before they find their rhythm, Eric Musselman’s teams have never quite stacked the deck. For three consecutive years, when Musselman arrived in Fayetteville, Arkansas didn’t play a single top-25 team across their nonconference slate before diving into SEC play. That changed, into 2023-24, when the Razorbacks took on powers North Carolina, Duke and Oklahoma in November and December as part of a rough-and-tumble season. But with Musselman’s return to Southern California roots this spring, and a roster carefully pieced together from transfer-portal remnants, he returned to a softer slate in the early months. That’s come in matchups and in travel, as USC hasn’t and won’t travel beyond Palm Desert for a single nonconference game this season. “When you take the two games in Palm Springs, and 20 league games, and Cal, that’s a good enough strength of schedule,” Musselman said, after USC’s early November opener against Chattanooga. The Trojans’ early-season slate, though, was as cushy a Musselman-led team has had in recent memory. And they bounced, quickly, to a 5-1 record, with four games against teams currently under .500. Then they traveled two hours east to the desert, and came away thoroughly embarrassed. USC’s 71-36 loss to Saint Mary’s on Thursday was the worst loss in program memory since Andy Enfield’s Trojans were smacked by TCU by 35 points in 2018. The underlying realities, too, were even uglier than the final score: USC shot 26% from the floor, went 0 for 12 from deep, recorded a total of six assists and were doubled in rebounding. After a subsequent loss to New Mexico on Saturday, any fuzzy feelings from Musselman’s early tenure have quickly faded, with the Trojans sitting at 5-3 entering their Big Ten debut against 12th-ranked Oregon on Wednesday night. With a roster of new faces, USC’s defensive identity still hasn’t clicked, and their offensive identity looks even more fragile. Entering conference play, here’s a breakdown of three key takeaways from the Trojans’ nonconference slate. Who are the late-game closers? USC’s roster was constructed on versatility, with Musselman often emphasizing that USC would turn smaller or bigger based upon game flow and style of opponent. But eight games in, it’s abundantly clear Musselman’s still tinkering, a development that suggests his program hasn’t yet found a consistent identity. Twelve Trojans have seen stints, of one form or another, in Musselman’s rotation in this early part of the season. In an 83-73 loss to New Mexico that had ballooned to a 20-point deficit with six minutes to play, USC closed with freshman Isaiah Elohim and sophomore Kevin Patton Jr., both of whom had rarely played for extended stretches. Center Josh Cohen is USC’s top scorer through eight games, but wasn’t on the floor late against Cal and New Mexico. It’s clear, at the moment, Musselman trusts USC’s wings to finish games more than relying on Cohen or another big. But precisely which wings, still, is yet to be determined. More Saint Thomas More does not mean more production. Through eight games, the Northern Colorado transfer is USC’s leader in rebounds, assists and steals, playing the kind of 6-foot-7 do-everything role Musselman saw early in his blend of ball-handling and physicality. “When we got the commitment, we felt like he was going to have to carry a load,” Musselman said in early November. But one key ingredient is missing: The fiery Thomas hasn’t been the go-to scorer he so often showed in exhibition games. He’s averaging just 8.3 points a game, shooting 37% from the floor and 25% from deep while often passing up shots in the flow of USC’s offense. These Trojans desperately need shot creators. Thomas consistently taking 10-plus shots a game and finding a rhythm would go a long way. Young Trojans in waiting For long stretches in USC’s first few games, Washington transfer Wesley Yates III has looked like USC’s best player and completely unaware of the concept of shot selection, a maddening conundrum that saw him score in double figures for four straight games before falling in Musselman’s rotation. “Wes has a great ability to score the ball, but he’s got a lot of things – as a lot of young players need to grow – and understand how to play with discipline on both ends of the floor,” Musselman said earlier in the year. Elohim, a Sierra Canyon product, has gotten a few looks but little consistent run to establish himself as a scorer. Patton Jr., a San Diego import, has seen some opportunity since returning from injury. Freshman Jalen Shelley looked dynamic in a preseason scrimmage, but has barely played. Musselman, thus far, has shown much more trust in his veteran transfers – keep an eye on the stock of USC’s youth quadrant.

XRP, Ripple’s native cryptocurrency, has surged in value, climbing to $1.90, and now has a current trading price of $2.29 (at the time of writing). It has solidified its position as the third-largest cryptocurrency by market cap in the world. The remarkable growth showcases Ripple’s growing influence in the crypto space as a leader in cross-border payment solutions. Amid this rise, 1Fuel is making waves as an emerging contender, with a lot of potential to become a significant player in the crypto space. 1Fuel revolutionizes cross-chain trading with a peer-to-peer marketplace, one-click technology, and advanced security features. All these features are opportunities for early investors who want to capitalize on innovations in decentralized finance. XRP surpasses 100 billion dollars in valuation Ripple (XRP) has surpassed 100 billion dollars and reached a major milestone, with its market cap now exceeding $130.86 billion. It is now the third-largest cryptocurrency by valuation. The price surge is driven by growing investor confidence, leading to optimism around regulatory changes and Ripple’s expanding ecosystem. Analysts also credit the emergence of XRP ETFs as one of the reasons why it has surpassed $100 billion and attracted higher demand for the token. Ripple’s network, which is powered by the native cryptocurrency XRP, is a leader in fast, low-cost international money transfers and currency exchanges. The unique utility of XRP has positioned it as a reliable asset in the top DEX wallets, allowing it to surpass major cryptocurrencies like Tether and Solana in market capitalization to become the third largest. As XRP’s popularity grows, platforms like Phantom Wallet have become integral for users who want to manage their digital assets securely. With the ongoing growth and adoption, XRP is solidifying its place as a dominant force in the blockchain industry. XRP vs. OFT: which is a better investment? When comparing XRP with 1Fuel OFT, you can see that they both offer investment opportunities but with contrasting trajectories. XRP already has a well-established position as the third-largest cryptocurrency by market cap at $130.86 billion and is widely adopted. But for XRP’s value to increase by 300%, the market cap would have to surpass 390 billion, something that would require massive capital inflow and years of planning to achieve. So while XRP’s utility and value make it a stable choice, the token is limited by its sheer size. In contrast, 1Fuel’s OFT is in its early stages, currently in presale with a much smaller market cap. This positions it as a high-growth opportunity investment for crypto enthusiasts. It is projected that OFT could experience over 10,000% growth upon its listing, driven by innovative features like cross-chain capabilities, a decentralized peer-to-peer marketplace, and one-click transaction technology. For early investors seeking high returns in a short timeframe, OFT’s starting point offers a higher growth potential than XRP. Like 1Fuel , there are different choices for securely managing crypto assets. Platforms like Phantom Wallet are excelling in user-friendly DeFi and NFT integrations, while Core Wallet provides robust features for managing blockchain systems. However, for investors prioritizing growth potential, 1Fuel has a promising trajectory with its OFT. It stands out as one of the best DEX wallets, with cross-chain trading and storage. https://1fuel.io/1Fuel to revolutionize decentralized wallets 1Fuel (OFT) is set to redefine the future of decentralized wallets, offering an impressive suite of features that set it apart from competitors. While established wallets like Core Wallet and Phantom Wallet are popular choices among crypto users, 1Fuel introduces groundbreaking innovations that make it emerge as the most comprehensive option in the crypto space. The platform combines diverse features like a crypto debit card, one-click P2P transactions, cross-chain transaction technology, and an inbuilt mixer for complete anonymity. Additionally, AI-powered tools provide tailored insights for crypto investors to maximize their trading potential. Top DEX wallets usually focus on specific functionalities like storing and transferring digital assets securely, but 1Fuel takes a step forward, offering users cutting-edge technology in a single ecosystem. The ongoing presale has already gathered immense attention, reaching over 48% completion in a few days. With about $235,000 raised and over 25 million tokens sold, investors have recognized the transformative potential of 1Fuel as a utility token and a DEX wallet, signaling a new era in decentralized finance. Conclusion: Investors keep buying OFT Even as XRP has climbed to a higher value, investors are leaning towards OFT due to its value as a token and wallet. The 1Fuel OFT live presale has built impressive momentum over the past few days, attracting the attention of investors as one of the best DEX wallets. The presale offers a unique opportunity for investors who want to take advantage of the low token price and priority access to crypto cards and cold storage. Learn more about 1FUEL. Click on the links below: Presale: https://www.1fuel.io/ Telegram: https://t.me/Portal_1Fuel X: https://x.com/1fuel_?s=21 Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp _____________ Disclaimer: Analytics Insight does not provide financial advice or guidance. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. You are responsible for conducting your own research (DYOR) before making any investments. Read more here.None

Lindsey Vonn competes in a pair of downhills, another step on her comeback trail at the age of 40(Reuters) - The U.S. government has approved the export of advanced artificial intelligence chips to a Microsoft-operated facility in the United Arab Emirates as part of the company's highly-scrutinized partnership with Emirati AI firm G42, Axios reported on Saturday, citing two people familiar with the deal. (Reporting by Devika Nair in Bengaluru; Editing by Paul Simao) Copyright 2024 Thomson Reuters .USC QB Miller Moss enters transfer portal after losing starting job to Jayden Maiava

The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitors The primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECIST The study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Israeli Ministry of Health (IMOH) has approved the use of Low Volume UNO (LV UNO) in a Phase 1b clinical trial of LV UNO in combination with anti-PD-1 therapy. The trial will be conducted at four sites in Israel and patient screening will begin in the first quarter of 2025. The Phase 1b trial (NCT05351502) is a clinical proof-of-concept trial that will assess the intratumoral administration of LV UNO in patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions, who have shown disease progression or prolonged stable disease (≥ 12 weeks) after receiving a single agent anti-PD-1 containing treatment. The trial, which is expected to enroll up to 20 subjects, is designed to assess the preliminary efficacy of LV UNO by objective response rate (ORR) and duration of response (DOR) per RECIST v1.1 and secondarily immune-related response via iRECIST. Safety and tolerability of LV UNO in combination with anti-PD-1 therapy, as well as its potential to enhance the type, density, and distribution of immune cells within the tumor microenvironment will also be observed. Topline data from the Phase 1b portion of the study are anticipated in the second half of 2025. “We are excited to initiate the Phase 1b trial of LV UNO, a potentially groundbreaking solid tumor treatment approach, in combination with PD-1 inhibitors,” said Dr. Jedidiah Monson, Chief Medical Officer of Beyond Cancer. “In preclinical studies, a single dose of UNO has been shown to increase PD-L1 expression and improve overall survival in animal models compared to anti-PD-1 alone. Further, Phase 1a human data that demonstrated immune system activation were presented at ASCO’s Key Opinion Leader Event held in June 2024. We look forward to the Phase 1b trial results to establish the basis of further investigation of UNO in combination with PD-1 inhibitors.” “The initiation of the Phase 1b trial represents a major step forward in our vision for personalized cancer treatment. We see UNO as a complementary therapy for future cancer treatment paradigms, particularly for patients with anti-PD-1 refractory or resistant disease, potentially offering more patients access to effective treatment,” stated Dr. Selena Chaisson, Chief Executive Officer, and Director of Beyond Cancer. About Nitric Oxide Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens. About UNO Therapy for Solid Tumors Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Ultra-high concentration Nitric Oxide (UNO) therapy is a completely new approach to preventing relapse or metastatic disease. In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models. Beyond Cancer, Ltd. believes that UNO has the potential to prevent relapse or metastatic disease with as little as a single 5-minute treatment and with limited toxicity or off-target effects. About Beyond Cancer, Ltd. Beyond Cancer, Ltd. is a development-stage biopharmaceutical and medical device company utilizing ultra-high concentration nitric oxide (UNO) via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in patients with solid tumors. Beyond Cancer is also conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols. For more information, visit www.beyondcancer.com . Forward Looking Statements This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks forward,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials concerning the ultra-high concentration nitric oxide product candidate; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for the ultra-high concentration nitric oxide product candidate; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; obtaining, maintaining and protecting intellectual property utilized by products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air, Inc.’s website. Beyond Cancer and Beyond Air undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law. CONTACTS: Corey Davis, PhD LifeSci Advisors, LLC Cdavis@lifesciadvisors.com (212) 915-2577 Matt Johnson, Head of Corporate Development & Strategy Beyond Cancer, Ltd. Mjohnson@beyondcancer.com